These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

784 related items for PubMed ID: 8874972

  • 1. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM, Ueno Y, Cunha BA.
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of BRL 42715, a beta-lactamase-inhibiting penem.
    Qadri SM, Ueno Y, Burdette M, Kroschinsky R, Almodovar E.
    Chemotherapy; 1991; 37(6):398-404. PubMed ID: 1760938
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K, Sailaja VV, Umabala P, Satheesh T, Lakshmi V.
    Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ, Prior RB.
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [Abstract] [Full Text] [Related]

  • 6. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ, Jin YF, Turner HL.
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [Abstract] [Full Text] [Related]

  • 7. Susceptibility of gram-negative bacteria and Staphylococcus aureus to combinations of ticarcillin and clavulanic acid.
    Casey P, Glauser M.
    Eur J Clin Microbiol; 1983 Dec; 2(6):541-7. PubMed ID: 6607834
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S, Singhal R, Sood S, Dhawan B, Das BK, Kapil A.
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [Abstract] [Full Text] [Related]

  • 9. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 10. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM, Seetulsingh P.
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [Abstract] [Full Text] [Related]

  • 11. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R, Duval J.
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [Abstract] [Full Text] [Related]

  • 12. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sader HS.
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [Abstract] [Full Text] [Related]

  • 13. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D, Mulgrave L, Munro R, Neville S, Smith H, Dimech W.
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [Abstract] [Full Text] [Related]

  • 14. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Pagani L, Migliavacca R, Luzzaro F, Giacobone E, Perilli M, Micheletti P, Amicosante G.
    Chemotherapy; 1998 May; 44(6):377-84. PubMed ID: 9755296
    [Abstract] [Full Text] [Related]

  • 15. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC, Sierra-Madero J, Washington JA.
    Diagn Microbiol Infect Dis; 1989 May; 12(6):511-5. PubMed ID: 2560423
    [Abstract] [Full Text] [Related]

  • 16. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T, Yokota E, Nakane T, Inoue E, Mitsuhashi S.
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC.
    Diagn Microbiol Infect Dis; 1989 Sep; 12(6):481-8. PubMed ID: 2560420
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT.
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [Abstract] [Full Text] [Related]

  • 19. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD.
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [Abstract] [Full Text] [Related]

  • 20. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
    Thomson KS, Weber DA, Sanders CC, Sanders WE.
    Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.